S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

被引：12

作者：

Maragno, Ana Leticia ^{[1
]}

Mistry, Prakash ^{[2
]}

Kotschy, Andras ^{[3
]}

Szlavik, Zoltan ^{[3
]}

Murray, James ^{[4
]}

Davidson, James ^{[4
]}

Le Toumelin-Braizat, Gaetane ^{[1
]}

Chanrion, Maia ^{[1
]}

Bruno, Alain ^{[5
]}

Claperon, Audrey ^{[1
]}

Maacke, Heiko ^{[2
]}

Morris, Erick ^{[6
]}

Wang, Youzhen ^{[6
]}

Derreal, Alix ^{[5
]}

Csekei, Marton ^{[3
]}

Paczal, Attila ^{[3
]}

Szabo, Zoltan ^{[3
]}

Sipos, Szabolcs ^{[3
]}

Proszenyak, Agnes ^{[3
]}

Balint, Balazs ^{[3
]}

Surgenor, Allan ^{[4
]}

Dokurno, Pawel ^{[4
]}

Matassova, Natalia ^{[4
]}

Chen, Ijen ^{[4
]}

Lysiak-Auvity, Gaelle ^{[1
]}

Girard, Anne-Marie ^{[1
]}

Grave, Fabienne ^{[1
]}

Colland, Frederic ^{[1
]}

Halilovic, Ensar ^{[6
]}

Geneste, Olivier ^{[1
]}

机构：

[1] Inst Rech Servier, Croissy Sur Seine, France

[2] Novartis Inst BioMed Res, Basel, Switzerland

[3] Servier Res Inst Med Chem, Budapest, Hungary

[4] Vernalis R&D Ltd, Cambridge, England

[5] Inst Rech Int Servier, Suresnes, France

[6] Novartis Inst BioMed Res, Cambridge, MA USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-4482

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4482

引用

页数：3

共 4 条

[1] MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies
Halilovic, Ensar
Chanrion, Maia
Mistry, Prakash
Wartmann, Markus
Qiu, Shumei
Sanghavi, Sneha
Chen, Yan
Lysiak, Gaelle
Maragno, Ana Leticia
Pfaar, Ulrike
Huth, Felix
Schoumacher, Marie
Claperon, Audrey
Kraus-Berthier, Laurence
Banquet, Sebastien
Derreal, Alix
Maacke, Heiko
Colland, Frederic
Geneste, Olivier
Morris, Erick
Wang, Youzhen
CANCER RESEARCH, 2019, 79 (13)
[2] Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor
Szlavik, Zoltan
Csekei, Marton
Paczal, Attila
Szabo, Zoltan B.
Sipos, Szabolcs
Radics, Gabor
Proszenyak, Agnes
Balint, Balazs
Murray, James
Davidson, James
Chen, Ijen
Dokurno, Pawel
Surgenor, Allan E.
Daniels, Zoe Marie
Hubbard, Roderick E.
Le Toumelin-Braizat, Gaetane
Claperon, Audrey
Lysiak-Auvity, Gaelle
Girard, Anne-Marie
Bruno, Alain
Chanrion, Maia
Colland, Frederic
Maragno, Ana-Leticia
Demarles, Didier
Geneste, Olivier
Kotschy, Andras
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (22) : 13762 - 13795
[3] Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models
Caenepeel, Sean R.
Belmontes, Brian
Sun, Jan
Coxon, Angela
Moody, Gordon
Hughes, Paul E.
CANCER RESEARCH, 2017, 77
[4] AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Flemington, Vikki
Davies, Emma J.
Robinson, David
Sandin, Linda C.
Delpuech, Oona
Zhang, Pei
Hanson, Lyndsey
Farrington, Paul
Bell, Sigourney
Falenta, Katarzyna
Gibbons, Francis D.
Lindsay, Nicola
Smith, Aaron
Wilson, Joanne
Roberts, Karen
Tonge, Michael
Hopcroft, Philip
Willis, Sophie E.
Roudier, Martine P.
Rooney, Claire
Coker, Elizabeth A.
Jaaks, Patricia
Garnett, Mathew J.
Fawell, Stephen E.
Jones, Clifford D.
Ward, Richard A.
Simpson, Iain
Cosulich, Sabina C.
Pease, J. Elizabeth
Smith, Paul D.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 238 - 249

← 1 →